jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Anti Hepatitis C Virus (HCV) - Total

Liver
image

Report in 8Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

The Anti-HCV Total test detects both IgM and IgG antibodies produced by the immune system in response to infection by the Hepatitis C virus

₹199₹935

79% OFF

Anti Hepatitis C Virus (HCV) - Total

  • Why is it done?
    • Detects antibodies produced in response to hepatitis C virus infection to determine if an individual has been exposed to or infected with HCV
    • Primary screening test used in patients with suspected hepatitis C or those at risk for HCV exposure
    • Routine screening for blood and organ donors, healthcare workers, and patients with liver disease
    • Evaluation of patients with unexplained elevated liver enzymes or chronic liver disease
    • Assessment in patients with risk factors including history of intravenous drug use, sexual exposure to HCV-positive individuals, or occupational exposure
    • Monitoring and confirmation following a positive rapid HCV test or exposure incident
  • Normal Range
    • Negative Result: No detectable anti-HCV antibodies; typically reported as "Negative", "Non-reactive", or "Not detected"
    • Positive Result: Anti-HCV antibodies detected; typically reported as "Positive", "Reactive", or as a numerical value (S/CO or sample-to-cutoff ratio > 1.0)
    • Units: S/CO (Sample-to-Cutoff ratio) for quantitative results, or qualitative as Positive/Negative
    • Interpretation: Negative indicates no prior exposure to HCV or absence of infection. Positive indicates exposure to HCV and requires confirmatory testing
  • Interpretation
    • Negative Result: No evidence of HCV infection or exposure. However, results may be negative during early infection (window period of 1-10 weeks before antibodies develop)
    • Positive Result: Indicates past or present HCV infection; confirms exposure to the virus. Does not differentiate between active infection and cleared infection (spontaneous or treatment-induced)
    • Borderline/Equivocal Result: Result near cutoff value; requires repeat testing or confirmatory test (HCV RNA by PCR, recombinant immunoblot assay, or supplemental antibody test)
    • Factors Affecting Results: Early infection (window period), immunocompromised states (may have false negatives), chronic kidney disease patients on hemodialysis, and liver transplant recipients
    • Clinical Significance: Positive anti-HCV antibodies warrant HCV RNA PCR testing to determine if active infection is present and to assess viral load for treatment decisions
  • Associated Organs
    • Primary Organ: Liver - HCV directly infects and replicates within hepatocytes, causing inflammation and potential cirrhosis
    • Associated Conditions: Chronic hepatitis C, cirrhosis, hepatocellular carcinoma, fatty liver disease, portal hypertension, esophageal varices
    • Extrahepatic Manifestations: Cryoglobulinemia, glomerulonephritis, autoimmune thyroiditis, B-cell lymphoma, vasculitis, and peripheral neuropathy
    • Complications: Liver failure, variceal bleeding, ascites, hepatic encephalopathy, renal dysfunction, and increased risk of infection
  • Follow-up Tests
    • Confirmatory Testing (if Positive): HCV RNA PCR (qualitative and/or quantitative) to confirm active infection and determine viral load
    • HCV Genotyping: Determine HCV strain to guide treatment decisions and predict treatment response
    • Liver Function Tests: AST, ALT, alkaline phosphatase, bilirubin, albumin to assess liver injury and synthetic function
    • Liver Fibrosis Assessment: FIB-4 index, AST-to-platelet ratio index (APRI), transient elastography (FibroScan), or liver biopsy to stage fibrosis
    • HCV Core Antigen: May be used as alternative confirmatory test or for monitoring viral replication
    • Hepatitis A and B Serology: Screen for co-infections with other hepatitis viruses
    • HIV and Human T-cell Leukemia Virus (HTLV) Testing: Screen for concurrent blood-borne infections in at-risk patients
    • Post-Treatment Monitoring: HCV RNA PCR at 12 weeks after completion of direct-acting antiviral therapy (SVR12) or 24 weeks (SVR24) to confirm viral clearance
  • Fasting Required?
    • Fasting: No
    • Special Instructions: No fasting is required for this test. Patient may eat and drink normally. Blood can be drawn at any time of day
    • Medications: No medications need to be withheld for this test; all regular medications may be taken as prescribed
    • Specimen Collection: Standard venipuncture with serum separator tube (SST) or equivalent collection tube; approximately 5-10 mL of blood
    • Pre-Test Preparation: No specific preparation needed; patient should remain seated for 5 minutes before blood draw to ensure proper blood pressure and fluid distribution

How our test process works!

customers
customers